Granted projects - IOF
2020
- Stefaan De Smedt - Galcer integrated liposome system for mRNA vaccines - 2020-2021
2019
- Bruno De Geest - Polymer lipid carrier systems for molecular immune modulators - 2019-2020
- Daisy Flamez, An Van Den Bulcke, Dominic De Groote, Koen Tyberghein, David Aubert, Frederick Leys, Catherine Van Der Straeten & Bianka Kühne - CRIG platform medewerker - 2019-2024
- An Hendrix - Validation of a method that uses bacterial extracellular vesicles as biomarker for intestinal barrier permeability and microbial dysbiosis - 2019
- Richard Hoogenboom - BioGelator: a self-assembling peptide platform for subcutaneous injection (BioGelator) - 2019
- Tessa Kerre - Cancer in Motion - 2019-2020
- Georges Leclercq - Strengthening the UGent patent position on an improved culture method for adoptive cell therapies (immuno-oncology) - 2019-2020
- Karim Vermaelen - MIDRIX, a unique method for the production of dendritic cell therapy against solid cancers: strengthening of intellectual property - 2019
2018
- Chris Stevens - Development of first-in-class invasione inhibitorts for the treatment of metastatic cancer (Chalcone 3) - 2018
- Sandra Van Vlierberghe & Philip Blondeel - Development of a gel for fat grafting for breast reconstruction - 2018
2017
- Johan Van der Eycken & Olivier De Wever - Pelofen, a novel microtubule stabilizing agent for second-line treatment strategies in multidrug - 2017
2016
- Kevin Braekmans & Olivier De Wever - Extracellulair vesicle (EV) diagnose met behulp van Surface-Enhanced Raman Spectroscopy (SERS) (Exosomes SERS) - 2016-2017
- Nico Callewaert - Glyco (Double) Strikethrough technology: maturation, development of compatible GlyConnect coupling technology (Glyco Double Delete) - 2016-2018
- Olivier De Wever - Reference standard EV purification (EV-REF) - 2016-2018
- Daisy Flamez, An Van Den Bulcke & Dominic De Groote - Hefboom ter opschaling van valorisatie voor het Cancer Research Institute Ghent (CRIG) - 2016-2019
- Davy Vanden Broeck & Jo Vandesompele - In situ methylation hybridization: visualization of methylation patterns using UPSAS - 2016-2017
- Jo Vandesompele - miRNA Chemoresistance - 2016-2018
- Jo Vandesompele & Pieter Mestdagh - Therapeutic application of SAMMSON lncRNA inhibition in ocular melanomas and non-melanoma tumors (SAMMSON) - 2016-2019
2015
- Wim Ceelen - Development of a new peritoneal catheter for improved chemotherapy (Peritoneal Catheter) - 2015-2016
- Wilfred De Neve - Building a benchfor positioning patients undergoing radiotherapy for breast cancer (Breast Couch) - 2015-2016
- Olivier De Wever - Use of the small GTPase Rab27B to diagnose and treat poor prognosis of estrogen receptor positive (ER +) breast cancer (Rab27b-diagnostic) - 2015-2016
- Serge Van Calenbergh - Pharmacological feasibility of a drug discovery opportunity for a new cancer therapy immunotherapy (Immunomodulators) - 2015-2017
2014
- Matthias D'hooge - Opportunity to develop new HDAC6 inhibitors for therapeutic use (HDAC6 inhibitors) - 2014-2017
- Chris Stevens - An opportunity to develop new invasion inhibitors for the treatment of metastatic cancers (Chalcone2) - 2014-2016
- Johan Van De Eycken - New simplified peloruside cytoxins that overcome Taxol resistance (Peloruside 2) - 2014-2015
- Jo Vandesompele - lncRNA as therapeutic targets and diagnostic biomarkers for advanced melanoma (lncRNA) - 2014-2016
2013
- Nico Callewaert - GlycoCirrhoTest: production demonstration, CE mark preparation and building a link to pathology of cirrhotic liver regeneration - 2013-2016
- Johan Van De Eycken - Simplified Peloruside analogues for anti-cancer and anti-Alzheimer's therapies (Peloruside) - 2013-2014
2012
- Chris Stevens - Hit-to-lead evaluatie van chalconanaloga voor gebruik als anti-invasieve kankertherapie - 2012-2014
2011
- Savvas Savvides - Validation of the hematopoietic Flt3-D3 ectodomain as a new target for cancer and immunostimu (Flt3-D3) - 2011-2012
- Karim Vermaelen - Enhance unwanted macrophage phagocytosis by damaging sialoadhesin tumor-derived apoptosis (Phagoblock) - 2011-2012